• Investment World
• eWorld
• Brand Line
• Mentor
• Life
• Brand Quest
• The New Manager

Stocks

• Quotes
• SE Diary
• Scoreboard
• Open-End Mutual Fund

Cross Currency

• Rates
  
  

Shipping

• Ports
  
  

Archives

• Yesterday
• Datewise
• Resources
• In Focus
• In Depth
• Events 2007

Group Sites

• The Hindu
• The Hindu ePaper
• Business Line
• Business Line ePaper
• Sportstar
• Frontline
• The Hindu eBooks
• The Hindu Images

Hyderabad, Jan. 23

Suven Life Sciences Ltd has bagged a second product patent from the US for its selective serotonin receptor affinity compounds, which are being developed as therapeutic agents. According to the invention patent disclosure, the compounds were useful in the treatment of neurodegenerative disorders such as Alzheimer’s, Parkinson, Schizophrenia and Huntington’s. “We are very pleased by the issuance of this patent to Suven by the US Patent office for our drug candidates that are being developed for CNS disorders which targets a $18-billion potential market opportunity,” Mr Venkat Jasti, Chief Executive Officer, Suven, said in a release.

— Our Bureau

More Stories on : IPR | Pharmaceuticals

Article E-Mail :: Comment :: Syndication :: Printer Friendly Page

Stories in this Section
Cipla gets notice on ‘overcharging’

Copyright © 2008, The Hindu Business Line. Republication or redissemination of the contents of this screen are expressly prohibited without the written consent of The Hindu Business Line